OSCR Looks 33.9% Overvalued on GF Value™ as Oscar Health Revises
Oscar Health (OSCR) revised its 2026 forecasts, raising operating earnings outlook by $100M to $600M-$800M and improving medical loss ratio guidance. Revenue guidance remains $18.7B-$19B. GF Value™ indicates OSCR is 33.9% overvalued at $32.44. The company has a strong GF Score™ of 83/100, with high growth and momentum ratings but middling profitability and valuation. Insiders have sold significantly more shares than they've bought.
How this was made
The 30-second read
Why it matters
The guidance lift suggests improved cost management, likely prompting a price uptick, but insider selling and valuation premium raise caution.
Market read
Guidance update is material for OSCR traders and may influence health‑insurer sector sentiment.
What to watch
Potential headwinds from regulatory changes to ACA markets and competition from larger insurers.
Background
Oscar Health disclosed an upward revision to its 2026 earnings and loss‑ratio guidance ahead of its Investor Day.
Ticker impact
Oscar Health raised its 2026 operating earnings outlook by $100 million and improved its medical loss ratio guidance, indicating better cost control.
upward pressure over the next few trading sessions
Guidance beat expectations and shows improved profitability, which traders typically reward.
Market effects
May boost sentiment for health‑tech insurers and peers.
U.S. market focus, limited regional effect.
Low; primarily a U.S. health‑insurance story.
Counterpoint
Insider net selling and a 33.9% valuation premium could signal overvaluation risk.
Key entities
- companyOscar Health Inc.
U.S. technology‑driven health insurer (ticker OSCR).
